Brain Tumor Drugs Market Size, Share & COVID-19 Impact Analysis, By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others), By Indication (Meningioma, Pituitary Tumors, Glioblastoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and Regional Forecast, 2021-2028

The global brain tumor drugs market size was USD 2.35 billion in 2020. The global impact of COVID-19 has been unprecedented and staggering, with brain tumor drugs witnessing a positive demand shock across all regions amid the pandemic. Based on our analysis, the market exhibited a stellar growth of 18.4% in 2020. The market is expected to grow from USD 2.83 billion in 2021 to USD 5.64 billion in 2028 at a CAGR of 10.4% in the 2021-2028 period. The sudden decline in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.

Cancer is a foremost public health problem globally and is the second leading cause of death in the United States. According to the National Brain Tumor Society, there are around 700,000 Americans living with primary brain cancer, and approximately 84,170 people are estimated to receive a primary brain tumor diagnosis in 2021. This market entails drugs used to treat the human brain for the mass growth of abnormal cells.  Depending on the size, type, and location of the tumor, such drugs are either used alone or in combinations. For example, Everolimus, BiCNU Carmustine, Avastin (Bevacizumab), and Temozolomide are some of the drugs used for the treatment of brain tumors.

On the other hand, the burden of the rising prevalence of oncological diseases and the growing geriatric population globally is leading to a surge in the sales of products, as well as clinical trials in the global market. Moreover, initiatives taken by the government to enhance healthcare infrastructure, coupled with collaborative efforts by pharmaceutical companies, for spreading awareness about the availability of various therapies are expected to accelerate the market growth during the forecast period.

For example, in May 2020, Penn Medicine collaborated with Intel to develop a new artificial intelligence approach to detect brain tumors. This collaboration is worth USD 1.2 million and is funded by the Informatics Technology for Cancer Research Program of the National Institutes of Health for three years.

COVID-19 Pandemic to Affect Growth Positively Backed by Investments in Quality Control

The outbreak of COVID-19 has had a positive impact on the brain tumor drugs market globally. Certain segments have witnessed a growth in the demand for drugs with respect to the COVID-19 emergency. Pharmaceutical companies involved in this market have significantly improved their supply chain management, enhanced the capabilities of their R&D, and invested more in their manufacturing management and quality control.

For instance, according to the quarterly reports of 2020 Roche, its global supply chain of medicines and diagnostic tests remain intact, and the sales of the pharmaceutical division rose by 7% as compared to the previous year. This growth was attributed to the efficacy of oncology drugs such as Tecentriq and Perjeta. The other leading key players have observed a similar brain tumor drugs sales scenario. They witnessed a growing demand for oncology drugs globally. Market players have been responsive to this increasing demand for oncology drugs amid the COVID-19 pandemic globally.

LATEST TRENDS

Request a Free sample to learn more about this report.

Robust R&D by Companies to Improve Treatment Options is a Vital Trend

The fundamental aim of companies operating in the global market is to provide effective cure options for improving brain tumor treatment. Consequently, to materialize this aim, industry players are putting enormous efforts into R&D through strategic agreements, mergers, and mounting funding. For example, in December 2018, Moleculin Biotech, Inc. entered into an agreement with Emory University to assist the expanded cancer research on Moleculin's WP1066 molecule for the potential treatment medulloblastoma, a pediatric malignant primary brain tumor. Accordingly, the demand for novel drugs is expected to boost the R&D of companies during the forecasted timeframe.

DRIVING FACTORS

Growing Incidence and Prevalence of Neurological Disorders to Propel Product Demand

Globally, the rapidly increasing prevalence of neurological disorders are identified in adults and children is augmenting the market growth. Brain disorders, which comprise an amalgamation of psychiatric, developmental, and neurodegenerative diseases, are a rising cause of morbidity globally. This can largely be attributed to the increasing geriatric population. According to the American Medical Association (AMA), by 2050, more than 20% of the global population is expected to be aged over 65 years. Furthermore, at least 60% of individuals aged 65 years and above will be living with more than one chronic condition by 2030. Thus, the rising incidence of these neurological disorders worldwide is the major factor propelling the brain tumor drugs market growth.

Robust Drug Pipelines to Generate New Growth Opportunities

Research and development to provide advanced patient care for brain disorders are accelerating globally. Innovative experiments leading to combination therapies with new or existing drug molecules have led to a rise in the number of pipeline candidates for brain tumor drugs. For Instance, in September 2019, Mateon Therapeutics Inc. announced that the U.S. FDA had accepted the new drug application of OT101/Trabedersen to treat diffuse intrinsic pontine glioma (DIPG) as a drug for a rare pediatric disease.

RESTRAINING FACTORS

Rising Use of Targeted Therapies to Restrict Market Growth

The growing use of targeted therapies will act as a major restraining factor. Targeted cancer drugs target the elimination of cancer cells without harming the normal cells. Targeted therapy has proven to be more efficacious and inflict limited side effects when compared to conventional chemotherapy and radiation therapy procedures.

For instance, Everolimus, a targeted drug molecule that precisely inhibits the tumor cells from the division is gaining popularity in the treatment of cancer around the world. Likewise, Bevacizumab averts the renewal of cancer cells, unlike cytotoxic chemotherapy drugs that inhibit the division of normal cells as well. Thus, the increasing acceptance of these therapies is likely to disturb the revenue generated by traditional brain tumor drugs, thus hampering the market's growth during the projected time frame.

SEGMENTATION

By Therapy Type Analysis

Targeted Therapy Segment to Lead Stoked by Rising Awareness of Precision Medicine

Based on the therapy type, the global market has been segmented into chemotherapy, targeted therapy, immunotherapy, and others. Among them, the targeted therapy segment computed a significant share in the year 2020. The predominant factor influencing the dominance of this segment in the global brain cancer drugs market is the increasing awareness regarding precision medicine. A robust pipeline of targeted therapies under development for the treatment of brain cancer is estimated to be responsible for the growth of the segment in the coming years.

For instance, Array BioPharma is currently investigating the safety of its targeted therapy ARRY-380 in Phase 1 clinical trial to treat brain cancer metastasized from breast cancer.

Immunotherapy drugs are gaining traction for brain tumor treatment across all regions. This is attributed to the higher efficacy and lower adverse effects associated with the use of this therapy. However, the higher adoption and dependence on chemotherapy drugs in emerging economies are projected to affect the adoption of upcoming therapies in these regions critically.

By Indication Analysis

To know how our report can help streamline your business, Speak to Analyst

Rising Incidence of Glioblastoma is Projected to Drive the Segment

On the basis of indication, the global market is classified into glioblastoma, meningioma, pituitary tumors, and others. The glioblastoma segment accounted for around 47% share in the global market in 2020. The higher prevalence of glioblastoma is estimated to be the major driving factor responsible for the growth of the disease indication in the market. Advancements in diagnosis technologies have improved the awareness and early diagnosis of the brain tumor type among the general public.

According to the American Association of Neurological Surgeons (2017), glioblastoma (GBM) has a yearly incidence of 2-3 per 100,000 Individuals in the U.S. GBM also accounts for over 52% of the total primary tumors.

Meningioma is a comparatively rare brain tumor type. The American Society of Clinical Oncology (ASCO) estimated that over 34,000 individuals might be diagnosed with meningioma in 2020. The pituitary tumor segment accounted for the smallest share in the market, followed by other tumor types.

By Distribution Channel Analysis

Increasing Sales of Prescription-based Drugs to Support Hospital Pharmacy Segment

Based on the distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacy segment captured the lion’s share worldwide owing to the higher sales of prescription-based drugs and rising patient visits for treatment against oncology diseases, especially brain cancer.

The retail pharmacy segment is also gaining prominence in the market because of the increasing customer reach and rising availability of prescription drugs in retail channels.

The others segment, which includes pharmacy, is expected to witness a lucrative CAGR over the forecast period due to the internet's penetration in emerging countries.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The market size in North America stood at USD 1.12 billion in 2020. The dominance of this region in this market is attributable to the higher diagnosis rate of tumors such as glioblastoma in the U.S. Higher access to advanced treatment is also anticipated to contribute to the dominance of the region. Another predominant factor influencing the expansion of the regional market is the frequent launch of innovative products combined with the strong presence of major players in the region.

Based on revenue, Europe secured the second-largest position in the market in 2020, attributed to the higher R&D funding and investments in the innovation of novel brain cancer drugs. This, combined with robust government initiatives for increasing awareness and access to brain tumor treatment, is anticipated to fuel the growth of brain tumor market over the forecast duration.

Asia Pacific region is expected to exhibit the highest CAGR owing to the increasing demand for oncology drugs, rising prevalence of brain cancer, and increasing geriatric population in countries such as China and Japan.

To know how our report can help streamline your business, Speak to Analyst

On the other hand, the Middle East and Africa and Latin America are projected to exhibit a comparatively slower growth rate due to the lower incidence rate of brain cancer and the lack of product approvals in these regions.

KEY INDUSTRY PLAYERS

Robust Brand Presence of Novel Products to Improve Sales of Industry Players

The market is fragmented owing to the presence of multiple players focusing on brain tumor drugs. Their brand presence is attributable to the strong sales of tumor drugs, coupled with the launch of novel therapies. Moreover, the emergence of new players during the forecast period and multiple product approvals are projected to extend the scope of the global market.

LIST OF KEY COMPANIES PROFILED:

• Pfizer Inc. (New York, U.S)


• F. Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Basel, Switzerland)


• Y-mAbs Therapeutics, Inc. (U.S)


• Merck & Co. Inc. (New Jersey, U.S)


• Johnson & Johnson (New Jersey, U.S)


• AstraZeneca (Cambridge, U.K)


• Bristol-Myers Squibb (New York, U.S)


• Other Players

KEY INDUSTRY DEVELOPMENTS:

• January 2020 – National Brain Tumor Society (NBTS) announced the commitment of at least $200,000 to support an upcoming phase II clinical trial of the investigational therapy, ONC201, for multiple years of funding.


• December 2020 – The approval of an investigational new drug application will allow Berubicin’s manufacturer to begin the study of the investigational drug in adults with glioblastoma who have earlier failed their first treatment.

REPORT COVERAGE

An Infographic Representation of Brain Tumor Drugs Market

View Full Infographic

To get information on various segments, share your queries with us

The global brain tumor drugs market research report provides a detailed analysis of the market. It focuses on key aspects such as leading companies, drug class type, and leading drug indications. Besides this, it offers insights into the market trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the developed market in recent years.

Report Scope & Segmentation